Abbott Vaults Into Oral HCV Race; Near-Term Focus Is Humira, Split
This article was originally published in The Pink Sheet Daily
Executive Summary
The pharma did not offer much detail on plans to split into two publicly traded companies during its quarterly call, but did shed some light on its HCV pipeline one day ahead of EASL.